Once-weekly eloralintide leads to 20% weight loss in Phase II trial

Published Date: 12 Nov 2025

A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight loss up to 20% over 48 weeks in adults with obesity or overweight without type 2 diabetes.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Chronic Lymphocytic Leukemia

2.

According to a study, white Americans are overdiagnosing melanoma at an alarming rate.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

5.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot